When comparing patients with tumour reduction, stability or progression, we did not find significant differences in sex, age, clinical or pathological subtype, Ki67 index, p53 expression, tumour volume at diagnosis or preTMZ treatment, radiological invasion, presence of metastases, previous or concomitant radiotherapy, time from diagnosis to TMZ treatment, TMZ dose or duration of treatment or follow-up. This evidence concerns the gene MKI67 and neoplasm.